US FDA's recent draft guidance on on how industry can propose innovative Rx-to-OTC switches raised more questions than it answered, heightening the need for a rulemaking to clarify how sponsors can satisfy the agency's standards, says the Consumer Healthcare Products Association.
In comments submitted on the July draft guidance, the OTC industry trade group repeatedly urged the agency to publish a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?